1 Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Plot No. 02, Sector 17-A, Greater Noida, Gautam Buddha Nagar, Uttar Pradesh, India
2 Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector - 125, Noida, Uttar Pradesh, India
A total of 219 countries, areas, or territories have globally witnessed the existence of a novel Coronavirus (COVID-19) pandemic over the last few months, which posed serious threats to human health. The viral incubation period varies from 2 to 14 days. It has been observed that osteoporosis patients are likely to be at high risk of COVID-19 contracting sequelae. Osteoporosis is a chronic condition that reduces bone strength and increases the risk of fracture. Osteoporosis typically requires sustained therapeutic intervention to reduce the risks of further bone loss, structural integrity impairment and incidence of fractures. In the COVID-19 pandemic, diagnosis of chronic osteoporosis conditions should not become an unwanted casualty. Metabolic bone condition may lead to complications in COVID-19 infected patients. Orthopaedic doctors are being redeployed in different hospitals to treat COVID-19 infected patients. Thus, the orthopaedics community needs compulsory training to understand the symptoms of this condition. Orthopaedics surgery and trauma surgery are challenging in a hospital setup with limited availability of hospital staff and operating facilities. Clinicians must respond to the challenges raised by this crisis and consider ways of continuing to help patients with chronic diseases with their substantive morbidity and mortality.
Keywords: Bone disorder, COVID-19, Infection, Osteoporosis, MERS-CoV, SARS-CoV2.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
* Address correspondence to this author at Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector - 125, Noida, Uttar Pradesh, India; Tel: +91-9459234530; E-mail: firstname.lastname@example.org